Compare Ford Motor Company (F) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ford Motor Company vs GSK plc — how do they compare? Ford Motor Company trades at $12.19 (market cap $48.85B), while GSK plc trades at $46.6 (market cap $91.88B). The key difference: GSK plc is the larger of the two by market cap, and Ford Motor Company pays the higher dividend (4.9%). Which is the better fit depends on your goals — on Pluang, investors hold Ford Motor Company for 105 Days and GSK plc for 93 Days on average.
| F | GSK | |
|---|---|---|
Market Cap | $48.85B | $91.88B |
Volume | 57,748,965 | 7,730,529 |
Sector | Consumer Cyclical | Health |
52-Week High | $17.44 | $61.18 |
52-Week Low | $11.21 | $43.24 |
Typical Hold Time | 105 Days | 93 Days |
Enterprise Value | $180.81B | $111.88B |
Dividend Yield | 4.9% | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ford Motor Company (F) trades at $12.23, up 0.87% with a mixed technical picture showing bearish moving averages but neutral oscillators. Fundamentally, the company reported a net loss of $8.18 billion in 2025 despite $187.27 billion revenue, with negative profit margins and high debt levels. Recent news highlights a 6.6% Q3 sales decline and supplier disruptions affecting F-150 production, though the company maintains its No. 3 U.S. sales position.
The outlook remains challenging with persistent losses and competitive pressures, though analyst consensus suggests 30% upside to the $15.90 price target. Key risks include ongoing operational issues, high leverage, and market share erosion to Asian rivals. Investment appeal hinges on execution improvements and hybrid vehicle transition success.
GSK trades at $46.45, down 1.21% with bearish technical signals. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 14.89 and EV/EBITDA of 8.75. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite near-term technical weakness.
GSK presents a mixed outlook with strong profitability and pipeline expansion offset by technical bearishness and HIV patent concerns. The company's 29.73% ROE and recent earnings outperformance support investment appeal, while the bearish moving average signal and competitive pressures warrant caution. Analyst consensus leans hold with 55% neutral rating, suggesting balanced risk-reward for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ford Motor Company
Ford Motor Company designs, manufactures, and services cars and trucks. The Company also provides vehicle-related financing, leasing, and insurance through its subsidiary.
Read more on F →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
